ELI LILLY & Co (LLY) Earnings History

6 quarters held1/5 transcripts analyzed2/30 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$23.0B+47.7%$7.1B$7.94Aug 5, 2026
LATESTEarnings filing (8-K)10-QFiled Aug 5, 2026, 7:05 AM ET
Earnings call · Aug 5, 2026
Q2 FY26YoY6M FY26
Revenue$23.0B1+47.7%$42.8B
Net income$7.1B+25.3%$14.5B
Op income$9.0B+30.7%$17.9B
EPS (dil.)$7.94+26.2%$16.19
EPS (basic)–––
Gross margin85.8%+1.5pp
Op margin39.1%-5.1pp
Net margin30.9%-5.5pp
  1. [1] “Revenue $ 22,974 $ 15,558 48%” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

revenue
$85.0B—$87.0B
eps_diluted
$35.50—$36.50
Q1 2026$19.8B–$7.4B$8.26Apr 30, 2026
Earnings filing (8-K)10-QFiled Apr 30, 2026, 7:03 AM ET
Earnings call · Apr 30, 2026deck
Q1 FY26YoY
Revenue$19.8B1–
Net income$7.4B–
Op income$8.9K–
EPS (dil.)$8.26–
EPS (basic)––
Gross margin81.9%-0.6pp
Op margin45.0%+16.0pp
Net margin37.4%+15.7pp
  1. [1] “Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound .” view source
Q3 2025$17.6B+54.0%$5.6B$6.21Oct 30, 2025
Earnings filing (8-K)10-QFiled Oct 30, 2025, 7:03 AM ET
Earnings calldeck
Q3 FY25YoY9M FY25
Revenue$17.6B+54.0%–
Net income$5.6B–$14.0B
Op income$7.4B–$17.9B
EPS (dil.)$6.21–$15.56
EPS (basic)–––
Gross margin82.9%+1.9pp
Q2 2025$15.6B+38.0%$5.7B$6.29Aug 7, 2025
Earnings filing (8-K)10-QFiled Aug 7, 2025, 7:05 AM ET
Earnings calldeck
Q2 FY25YoY6M FY25
Revenue$15.6B+38.0%–
Net income$5.7B+91.0%$8.4B
Op income$6.9B+85.0%$10.6B
EPS (dil.)$6.29+92.0%$9.35
EPS (basic)–––
Gross margin84.3%+3.5pp
Q1 2025$12.7B+45.0%$2.8B$3.06May 1, 2025
Earnings filing (8-K)10-QFiled May 1, 2025, 7:03 AM ET
Earnings calldeck
Q1 FY25YoY
Revenue$12.7B+45.0%
Net income$2.8B+23.0%
Op income$3.7B+47.0%
EPS (dil.)$3.06+23.0%
EPS (basic)––
Gross margin82.5%+1.6pp
Q4 2024$13.5B+45.0%$4.4B$4.88Feb 6, 2025
Earnings filing (8-K)10-KFiled Feb 6, 2025, 7:05 AM ET
Earnings calldeck
Q4 FY24YoYFY24
Revenue$13.5B+45.0%$45.0B
Net income$4.4B+101.0%$10.6B
Op income$5.1B+116.0%$12.9B
EPS (dil.)$4.88+102.0%$11.71
EPS (basic)–––
Gross margin82.2%+1.3pp

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

59 filings indexed · 68,876 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-08-05–3350
8-K2026-08-05Q2 202670
8-K2026-05-20–20
8-K2026-05-07–10
8-K2026-04-30Q1 202680
10-Q2026-04-30–3439
10-K2026-02-12–5370
8-K2026-02-04Q4 202570
8-K2025-11-21–10
8-K2025-10-30Q3 202570

Showing the latest 10 of 59 — the full set is in the API.

Related Research

Research

GLP-1 Drugs: What 977 SEC Filings Reveal

Analysis

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

Guides

Recession-Resistant Stocks 2026: 15 Companies Ranked by SEC Filing Data